CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-05 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 11,105 | ||
| 2025-07-29 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $36.45 | $182K | 388,108 |
| 2025-07-22 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 142,610 |
| 2025-07-22 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $37.47 | $75K | 140,610 |
| 2025-07-22 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 13,105 | ||
| 2025-07-15 | HENDERSON JOHN T Director | Grant or award | +559 | $38.01 | $21K | 74,240 |
| 2025-07-15 | Wysenski Nancy Director | Grant or award | +164 | $38.01 | $6K | 30,774 |
| 2025-07-15 | WIERENGA WENDALL Director | Grant or award | +164 | $38.01 | $6K | 32,345 |
| 2025-07-15 | Kaye Edward M. MD Director | Grant or award | +328 | $38.01 | $12K | 29,986 |
| 2025-07-15 | Harrington Robert Arthur Director | Grant or award | +328 | $38.01 | $12K | 22,643 |
| 2025-07-14 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $38.15 | $191K | 393,108 |
| 2025-07-08 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 142,610 |
| 2025-07-08 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $33.76 | $68K | 140,610 |
| 2025-07-08 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 15,105 | ||
| 2025-07-01 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $33.55 | $168K | 398,108 |
| 2025-06-17 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 142,610 |
| 2025-06-17 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $32.91 | $66K | 140,610 |
| 2025-06-17 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 17,105 | ||
| 2025-06-16 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $33.80 | $169K | 403,108 |
| 2025-06-05 | Kaye Edward M. MD Director | Sale 10b5-1 | −3,636 | $32.10 | $117K | 29,658 |
Page 18 of 22 · 429 trades